Erdafitinib API Powder: Uses, Benefits, Specifications, and Buyers

Meta title: Erdafitinib API Powder: Uses, Specifications and Buyers
Meta description: Learn what Erdafitinib API powder is, its medical use, specifications, buyers, and quality requirements for pharmaceutical manufacturing.

Erdafitinib is a targeted oncology medicine.
It belongs to the fibroblast growth factor receptor inhibitor class.
Manufacturers use erdafitinib API to produce pharmaceutical dosage forms.

The finished medicine trades under the brand name Balversa.
The active pharmaceutical ingredient is erdafitinib. (FDA Access Data)

Erdafitinib has gained attention in oncology.
It targets specific genetic changes linked to FGFR3.
Therefore, it supports a precision-medicine approach to cancer treatment.

This article explains erdafitinib API powder in a professional context.
It covers its identity, applications, buyers, and quality considerations.

What Is Erdafitinib API Powder?

Erdafitinib API means the active pharmaceutical ingredient erdafitinib.
API stands for Active Pharmaceutical Ingredient.

The API provides the pharmacological activity in a finished medicine.
Pharmaceutical manufacturers formulate it into approved dosage forms.

Erdafitinib has the chemical formula C25H30N6O2.
Its molecular weight is about 446.5 g/mol. (PubChem)

The CAS number for erdafitinib is 1346242-81-6.
The FDA substance database also lists its UNII.

The FDA describes erdafitinib as a yellow powder.
It also reports limited solubility in aqueous media. (FDA Access Data)

Therefore, buyers should distinguish API powder from tablets.
The API represents the raw active ingredient.
Balversa represents the finished prescription medicine.

Erdafitinib Chemical Identity

Erdafitinib has several identifiers used by industry databases.
These identifiers help manufacturers confirm material identity.

Common identifiers include:

• INN: Erdafitinib
• CAS: 1346242-81-6
• Molecular formula: C25H30N6O2
• Molecular weight: 446.5 g/mol
• UNII: 890E37NHMV
• Development code: JNJ-42756493
• Brand: Balversa

The FDA substance database confirms these core identity details.

What Is Erdafitinib Used For?

Erdafitinib has a specific role in oncology.
It treats certain advanced forms of urothelial carcinoma.

The FDA updated its indication in January 2024.
The current U.S. indication focuses on susceptible FGFR3 alterations. (U.S. Food and Drug Administration)

Patients need appropriate genetic testing before treatment.
The tumor must contain a susceptible FGFR3 genetic alteration.

Furthermore, the disease must meet the treatment criteria.
The FDA specifies prior systemic therapy in the indication. (FDA Access Data)

The European Union also authorizes erdafitinib.
The EMA approved Balversa across the EU in 2024. (European Medicines Agency (EMA))

The EU indication covers certain advanced urothelial cancers.
It requires susceptible FGFR3 genetic alterations.
It also specifies previous PD-1 or PD-L1 inhibitor treatment. (European Medicines Agency (EMA))

How Does Erdafitinib Work?

Erdafitinib belongs to the FGFR tyrosine kinase inhibitor group.
FGFR means fibroblast growth factor receptor.

FGFR signaling can influence cellular growth and survival.
Certain genetic changes can disrupt this signaling.

Erdafitinib blocks FGFR signaling activity.
This can reduce signaling associated with tumor-cell growth. (European Medicines Agency (EMA))

Consequently, treatment focuses on tumors with relevant biomarkers.
This approach represents targeted cancer therapy.

However, erdafitinib is not suitable for every cancer patient.
Doctors first evaluate the tumor’s molecular characteristics.

Erdafitinib API Powder Specifications

API buyers normally require comprehensive quality documentation.
A specification sheet should identify the material clearly.

However, exact acceptance limits vary between manufacturers.
They also depend on regulatory and manufacturing requirements.

Therefore, buyers should not rely on generic internet specifications.
They should request the supplier’s current specification and CoA.

Parameter	Erdafitinib API information
Product name	Erdafitinib
API type	Active Pharmaceutical Ingredient
CAS number	1346242-81-6
Molecular formula	C25H30N6O2
Molecular weight	446.5 g/mol
Appearance	Yellow powder
Pharmacological class	FGFR tyrosine kinase inhibitor
Main therapeutic area	Oncology
Main approved use	Selected advanced urothelial carcinoma
Target biomarker	Susceptible FGFR3 alterations
Identification	Confirmed by validated analytical methods
Assay	Supplier-approved specification
Related substances	Controlled under validated specification
Residual solvents	Controlled under applicable quality limits
Water content	Determined by validated method
Heavy metals / elemental impurities	Controlled under applicable standards
Storage	Follow supplier-approved stability conditions
Documentation	CoA and supporting quality documents

The molecular data come from FDA and PubChem records. (precisionFDA)

Quality Control for Erdafitinib API

Quality control plays a major role in pharmaceutical API sourcing.
Identity testing should confirm the correct molecular substance.

HPLC testing can assess assay and related substances.
Other analytical tests can examine residual solvents and water.

Depending on the application, buyers may request additional tests.
These can include elemental impurities and microbiological testing.

For commercial pharmaceutical use, documentation becomes especially important.
Buyers may request GMP information and manufacturing records.

They may also review the supplier’s quality system.
A Certificate of Analysis should accompany each commercial batch.

Who Buys Erdafitinib API Powder?

Erdafitinib API has a specialized pharmaceutical market.
Its buyers usually operate within regulated industries.

Pharmaceutical Manufacturers

Pharmaceutical companies can purchase API for finished products.
They may manufacture tablets or other approved dosage forms.

These companies normally require extensive supplier qualification.
They also evaluate manufacturing consistency and analytical documentation.

Contract Development and Manufacturing Organizations

CDMOs can purchase erdafitinib API for development projects.
They may support formulation and commercial manufacturing programs.

Similarly, contract manufacturers can require API for client projects.
Their requirements often include strict quality and traceability controls.

Pharmaceutical Distributors

Specialized API distributors can supply qualified pharmaceutical customers.
They may maintain regional inventories for approved buyers.

However, distributors must comply with applicable pharmaceutical regulations.
Requirements differ between countries and intended applications.

Research and Analytical Laboratories

Research organizations can use erdafitinib reference material.
Laboratories may study analytical methods and pharmaceutical formulations.

They may also use reference standards for method development.
Such materials require clear identity and documentation.

Why Buyers Request Erdafitinib API

The main commercial interest comes from targeted oncology.
Erdafitinib has a defined biomarker-driven therapeutic role.

Moreover, regulatory approvals support its pharmaceutical relevance.
The FDA approved erdafitinib in 2019. (FDA Access Data)

The FDA later granted traditional approval in January 2024.
That update focused on susceptible FGFR3 alterations. (U.S. Food and Drug Administration)

The EMA also authorized Balversa in the European Union.
Its European authorization took effect in August 2024. (European Medicines Agency (EMA))

Consequently, qualified API supply can support pharmaceutical production.
Nevertheless, buyers must verify regulatory requirements in their market.

Erdafitinib API Powder: Storage and Handling

Erdafitinib API requires controlled pharmaceutical handling.
Storage conditions should follow the manufacturer’s stability data.

The original packaging should protect the material from contamination.
It should also maintain appropriate environmental protection.

Manufacturers should follow their validated handling procedures.
They should also maintain batch traceability throughout the supply chain.

Importantly, API powder is not a consumer product.
It should not be used directly as a medicine.

Finished pharmaceutical products require validated formulation and manufacturing.
Clinical use also requires appropriate medical supervision.

What Documents Should API Buyers Request?

Professional buyers normally request several documents.
The exact document package depends on the intended use.

Common documents include:

• Certificate of Analysis
• Product specification
• Safety Data Sheet
• Batch information
• Manufacturing information
• Stability information
• Residual-solvent data
• Related-substance profile
• Analytical method information
• GMP documentation, where applicable
• Regulatory support documents, where available

A strong documentation package helps buyers assess material quality.
It also supports supplier qualification and regulatory review.

Conclusion

Erdafitinib API powder is a specialized oncology API.
It contains the active substance used in Balversa.

The compound targets fibroblast growth factor receptor signaling.
Its approved role focuses on selected urothelial carcinoma patients. (European Medicines Agency (EMA))

The key biomarker is a susceptible FGFR3 genetic alteration.
Therefore, molecular testing plays an important role in treatment selection.

Commercial API buyers include pharmaceutical manufacturers and CDMOs.
Specialized distributors and research laboratories also form part of the market.

For professional sourcing, quality documentation remains essential.
Buyers should verify identity, purity, impurities, and batch consistency.

They should also confirm regulatory suitability before purchasing material.
Finally, they should use the API only within qualified pharmaceutical processes.

References

1. U.S. FDA — Erdafitinib approval information
2. FDA — Balversa prescribing information
3. FDA Substance Registration — Erdafitinib
4. PubChem — Erdafitinib chemical and molecular data
5. European Medicines Agency — Balversa
6. EMA — Balversa product information